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Abstract
Background: Aberrant epigenetic silencing of tumor suppressor genes has been recognized as a driving force in
cancer. Epigenetic drugs such as the DNA methylation inhibitor decitabine reactivate genes and are effective in
myeloid leukemia, but resistance often develops and efficacy in solid tumors is limited. To improve their clinical
efficacy, we searched among approved anti-cancer drugs for an epigenetic synergistic combination with decitabine.
Results: We used the YB5 cell line, a clonal derivative of the SW48 colon cancer cell line that contains a single copy of
a hypermethylated cytomegalovirus (CMV) promoter driving green fluorescent protein (GFP) to screen for
drug-induced gene reactivation and synergy with decitabine. None of the 16 anti-cancer drugs tested had effects on
their own. However, in combination with decitabine, platinum compounds showed striking synergy in activating GFP.
This was dose dependent, observed both in concurrent and sequential combinations, and also seen with
other alkylating agents. Clinically achievable concentrations of carboplatin at (25 μM) and decitabine
reactivated GFP in 28 % of the YB5 cells as compared to 15 % with decitabine alone. Epigenetic synergy was
also seen at endogenously hypermethylated tumor suppressor genes such as MLH1 and PDLIM4. Genome-
wide studies showed that reactivation of hypermethylated genes by the combination was significantly better
than that induced by decitabine alone or carboplatin alone. Platinum compounds did not enhance
decitabine-induced hypomethylation. Rather, we found significantly inhibited HP1α expression by carboplatin and the
combination. This was accompanied by increased histone H3 lysine 4 (H3K4) trimethylation and histone H3 lysine 9
(H3K9) acetylation at reactivated genes (P < 0.0001) and reduced occupancy by methyl-binding proteins
including MeCP2 and methyl-CpG-binding domain protein 2 (MBD2) (P < 0.0001).
Conclusions: Our results suggest that the combination of decitabine with platinum analogs shows epigenetic
synergy that might be exploited in the treatment of different cancers.
Keywords: 5-aza-2′-deoxycytidine, Carboplatin, DNA methylation, Epigenetic reactivation, Tumor suppressor
genes
Background
Epigenetic changes have been recognized in the past
decade as major drivers of different types of cancer [1, 2].
The involvement of DNA methylation and histone modifi-
cations in aberrant gene silencing has particular functional
roles in malignant progression. Aberrant DNA methylation
is frequently observed in human cancer and contributes to
malignant transformation by silencing multiple tumor sup-
pressor genes [2]. DNA methylation at gene promoters re-
cruits methyl-binding proteins (MBPs) that are associated
with histone deacetylases (HDACs) as well as histone
methyltransferases [3, 4]. Methylation at the histone H3
lysine 9 (H3K9) residue is considered as a key element of
promoting epigenetic silencing by recruiting heterochro-
matin protein 1 (HP1) in a repressive complex that modu-
lates chromatin structure locally as well as excludes
transcription factors [5, 6]. On the other hand, trimethyla-
tion at histone H3 lysine 4 (H3K4) and acetylation at
H3K9 residues are associated with gene transcription [7].
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Understanding of epigenetic alterations in cancer led
to treatment by targeting epigenetic modulators, an ap-
proach referred to as epigenetic therapy [1]. Several epi-
genetic drugs including DNA hypomethylation inducers
and histone deacetylase inhibitors are now approved by
the Food and Drug Administration for cancer treatment.
Also, combinations of these two types of drugs that
achieved more epigenetic reactivation are being tested
in several clinical trials [8–10]. 5-Aza-2′-deoxycytidine
(decitabine), a DNA hypomethylating drug, is approved
for the treatment of the myelodysplastic syndrome (MDS)
[11]. Decitabine is a deoxycytidine analog. After incorpor-
ating into DNA, it traps DNA methyltransferase in the
form of a covalent protein-DNA adduct, leading to DNA
replication-dependent hypomethylation [11].
Despite the rapid development of epigenetic ther-
apy, problems remain including primary and second-
ary resistance to epigenetic drugs and rare responses
in solid tumors [12–14]. Therefore, it is necessary to
identify more efficient approaches in epigenetic drug
development as well as to develop better combination
therapy. Based on the hypothesis that activation of si-
lenced gene expression is part of the mechanism of
action of these drugs [15–17], we established the YB5
cell line derived from the SW48 colon cancer cell line
to develop a screening system for epigenetic drug
reactivation in cancer [18, 19]. YB5 contains a hyper-
methylated cytomegalovirus (CMV) promoter driving
a green fluorescent protein (GFP) reporter. YB5 has a
stably integrated single copy of this transgene, and
the locus is transcriptionally silent, with high levels of
DNA methylation, histone deacetylation, and nucleo-
some occupancy [18, 19]. Hypomethylating drugs re-
activate the CMV promoter and drive GFP expression
to high levels which can be easily scored by flow cy-
tometry analysis. Here, we used this system to test
whether known anti-cancer drugs have epigenetic ef-
fects alone or could enhance decitabine epigenetic
therapy. We discovered an epigenetic synergy between
platinum analogs and decitabine, which we trace to
HP1α degradation and chromatin remodeling.
Results
Decitabine and platinum analogs synergistically activate
GFP
We initially selected 18 commonly used anti-cancer
drugs to test for GFP reactivation including anthracy-
cline antibiotics, alkylating agents, topoisomerase inhibi-
tors, antimicrotubule agents, antitumor antibiotics, and
antimetabolites (Table 1). None of the 16 evaluable drugs
significantly activated GFP by themselves (the two tested
anthracyclines were autofluorescent and thus could not be
Table 1 A list of anti-cancer drugs used for screening of GFP reactivation
Drugs (dose range tested) Category Conc. producing the highest GFP GFP % ± SEM drug alone GFP ratio (±SEM)a
Carmustine (50–100 nM) Alkylating agent 50 nM 0.1 ± 0.1 0.86 ± 0.15
Mechlorethamine (50–100 nM) Alkylating agent 100 nM 0.2 ± 0.2 1.82 ± 0.1c
Carboplatin (50–75 μM) Alkylating agent 75 μM 0.4 ± 0.1 1.86 ± 0.83c
Oxaliplatin (5–20 μM) Alkylating agent 20 μM 2.2 ± 2.0 1.58 ± 1.1
Cisplatin (200–500 nM) Alkylating agent 500 nM 0.1 ± 0.1 1.07 ± 0.14
Chlorambucil (10–50 μM) Alkylating agent 50 μM 0.3 1.1
Temozolomide (50–75 μM) Alkylating agent 75 μM 0.2 1.28b
Fludarabine (10 μM) Antimetabolite 10 μM 0.1 ± 0.1 0.99 ± 0.45
Cytarabine Antimetabolite 10 nM 0.1 1.21 ± 0.24
Gemcitabine (100–400 nM) Antimetabolite 200 nM 0.9 0.86
Fluorouracil (100–400 nM) Antimetabolite 200 nM 0.2 ± 0.1 0.48 ± 0.28
Clofarabine (100–500 nM) Antimetabolite 100 nM 0.1 0.04
Irinotecan (25–100 nM) Topoisomerase I inhibitor 25 nM 0.2 ± 0.1 1.47 ± 0.12c
Etoposide Topoisomerase I inhibitor 100 nM 0.2 0.87 ± 0.07
Paclitaxel (1–10 nM) Antimicrotubule agent 10 nM 2.2 ± 0.8 0.92 ± 0.04
Mitomycin C Antitumor antibiotic 100 μg/mL 1.1 ± 0.8 1.1 ± 0.1
Doxorubicin Anthracycline antibiotic ND (autofluorescent)
Idarubicin Anthracycline antibiotic ND (autofluorescent)
In these experiments, anti-cancer drug treatment (for 24 h) was performed following decitabine pre-treatment at 100 nM for 72 h. GFP ratio was calculated for
each experiment by dividing the GFP signal obtained for the drug combination by the signal produced by decitabine alone for each experiment
aData shown were selected for doses producing the highest GFP percentage (±SEM)
bHigher concentrations of temozolomide of 200 and 250 μM in combination with decitabine produced respectively 30 and 41.4 % of GFP positive cells
cA significant increase in GFP ratio
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evaluated for GFP reactivation). By contrast, decitabine
showed GFP activation ranging from 15 % at 25 nM up to
40 % at higher doses, as previously reported [18]. We next
examined the combination of decitabine at a fixed low
dose of 25 nM (equal to 1/2 IC50) with a variety of doses
of the anti-cancer drugs. One category of drugs that
strikingly enhanced GFP reactivation by decitabine was
platinum analogs (Table 1). The IC50 of carboplatin and
cisplatin in YB5 cells was 25 and 2 μM, respectively. The
combination of decitabine at 25 nM with carboplatin or
cisplatin at doses of 0.5, 1.0, 1.5, 2, 2.5, and 3 times the
IC50 value showed a synergistic effect on GFP reactiva-
tion. GFP % gradually increased and peaked at 2× IC50 of
carboplatin and then decreased at higher doses (Fig. 1a).
At the optimal dose, carboplatin tripled the amount of
GFP+ cells. At the clinically achievable dose of 25 μM,
carboplatin increased GFP expression from 15 to 28 %.
Carboplatin was more efficient at boosting GFP reactiva-
tion than cisplatin, possibly because carboplatin has a
bidentate dicarboxylate ligand as its leaving group instead
of the more labile chloride ligands, and hence, its effects
are longer lasting [20].
We also performed sequential treatment of decitabine
followed by anti-cancer drugs. YB5 cells were treated
with several doses of each anti-cancer drug either alone
for 24 h or following a 72-h pre-treatment with decita-
bine at 100 nM. After decitabine pre-treatment alone,
13 ± 0.9 % of YB5 cells expressed GFP. Several of the
drugs enhanced GFP expression including carboplatin
and alkylating agents such as mechlorethamine and tem-
ozolomide (at high doses) that also significantly in-
creased GFP activation by decitabine, suggesting a class
effect. Interestingly, irinotecan, a topoisomerase I inhibi-
tor, also modestly increased GFP reactivation by decita-
bine (Table 1).
We next examined the effects of combining decitabine
and carboplatin on cell viability in YB5 and in two
leukemia cell lines (HL60 and K562). We used fixed ra-
tios of 1/8, 2/8, 3/8, 4/8, 6/8, and 8/8 IC50 for decitabine
and carboplatin in all respective cell lines. The combin-
ation of decitabine and carboplatin was synergistic in all
tested cell lines, indicated by combination index (CI)
values <1 (Fig. 1b–d). For example, the CI value of the
combination treatment ranged from 0.58 to 0.98 in YB5
Fig. 1 Gene expression and cell killing synergy of decitabine in combination with carboplatin. a. Effects of the combination of decitabine with
platinum analogs on GFP reactivation. YB5 cells were treated daily for 4 days with a fixed dose of decitabine at 25 nM (1/2 IC50) plus 0.5 to 3
IC50 doses of carboplatin or cisplatin, respectively. GFP was measured after the end of treatment by flow cytometry analysis. Standard deviation
was calculated based on two independent experiments. b–d Combination index (CI) plots of decitabine and carboplatin combinations in human
cancer cell lines. The cells were treated with decitabine alone, carboplatin alone, and decitabine plus carboplatin in fixed molar ratios based on
the IC50 values of each drug and incubated for 4 days. We used the ratios of 1/8, 2/8, 3/8, 4/8, 6/8, and 8/8 IC50 for decitabine and carboplatin
for each respective cell line. We assessed cell viability by counting of cells excluding trypan blue. The effects of combinations were estimated
using the CalcuSyn software, based on the median-effect method. CI < 1 indicates synergy, CI ~ 1 indicates additive effect, and CI > 1 means antagonism
Qin et al. Clinical Epigenetics  (2015) 7:97 Page 3 of 14
cells, from 0.67 to 0.82 in HL60, and from 0.2 to 1.0 in
K562 cell line. No antagonism (CI > 1.0) was observed.
Decitabine and carboplatin synergistically activate
transcription of silenced genes
In this cellular model, effects of decitabine on gene ex-
pression are through transcription [18]. To determine
whether this was also the case for the apparent synergy,
we used quantitative reverse transcription polymerase
chain reaction (qRT-PCR) to examine mRNA expression
of GFP and of endogenously silenced genes. Compared
to control cells, decitabine at a low dose (25 nM) ac-
tivated expression of GFP mRNA 10-fold, carboplatin
at 25 μM showed no significant activation, while the
combination of decitabine with carboplatin induced
expression 32-fold (P < 0.001, Fig. 2a). Furthermore,
the number of GFP fluorescent cells determined by
flow cytometry correlated well with GFP mRNA ex-
pression in YB5 cells treated with different doses of
carboplatin or cisplatin in combination with decita-
bine (R2 = 0.52, P = 0.004, Fig. 2b). Thus, the synergy
appeared to be transcriptional, suggesting epigenetic
effects. We next determined whether GFP mRNA ex-
pression could be a valid surrogate for reactivation of
endogenously silenced genes in YB5 cells, and whether
this was relevant in another cell type (HL60, a leukemia
cell line). We selected for analysis genes that showed pro-
moter DNA hypermethylation and transcriptional repres-
sion. Using qRT-PCR, we found that the addition of
carboplatin to decitabine enhanced activation of MLH1,
PDLIM4, and p16 (CDKN2A) expression in YB5 (Fig. 2c)
as well as of OLIG2 and NPM2 in HL60 (Fig. 2d).
We next analyzed the effect of decitabine and carbo-
platin on reactivation of hypermethylated genes at a
genomic scale. We combined data on gene expression
microarrays of untreated and drug-treated YB5 cells with
genome-wide DNA methylation data generated using
the quantitative, reduced representation-based method
called digital restriction enzyme analysis of methylation
(DREAM) [21], which queried the methylation status of
9083 gene promoters. Drug treatment consisted of deci-
tabine alone at 25 nM, carboplatin alone at 25 μM, or
the two drugs given concurrently. At baseline, there was
a strong inverse correlation (P < 2 × 10−16) between pro-
moter methylation and gene expression as expected, thus
confirming the accuracy of the genome-wide measure-
ments. A plot of expression vs methylation showed data
distribution in four quadrants: (Q1) unmethylated and
Fig. 2 Carboplatin enhanced gene transcription activated by decitabine. a. Carboplatin enhanced GFP mRNA expression in decitabine-treated
cells. YB5 cells were treated with decitabine 25 nM, carboplatin 25 μM, and decitabine + carboplatin for 4 days. GFP mRNA was measured by qPCR
and normalized to GAPDH. b. The correlation of GFP % measured by flow cytometry with GFP mRNA expression. We treated YB5 cells with a fixed
dose of 25 nM decitabine and a variety of doses of carboplatin or cisplatin. The broken line shows fit to a linear regression model. c. Reactivation
of expression of genes with methylated promoters in YB5. YB5 cells were treated with decitabine 25 nM, carboplatin 25 μM, and decitabine + carboplatin
for 4 days. d. Reactivation of expression of genes with methylated promoters in HL60. HL60 cells were treated with decitabine 200 nM, carboplatin
25 μM, and decitabine + carboplatin for 4 days. mRNA expression was measured by qPCR and normalized to GAPDH. Statistical significance of
Bonferroni-corrected t tests is shown by asterisks (**P < 0.01, ***P< 0.001, ****P< 0.0001)
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expressed (5697 genes), (Q2) methylated and expressed
(1119 genes), (Q3) unmethylated and silenced (479 genes),
and (Q4) methylated and silenced (1788 genes) (Fig. 3a,
Table 2). Because both decitabine and carboplatin are ex-
pected to have effects on gene expression independent of
DNA methylation, we analyzed the data in each quadrant
separately. We found 1943 genes showing at least 1.5-fold
expression change compared to the baseline (Fig. 3b) and
analyzed the gene expression changes in each quadrant
(Fig. 4). Carboplatin treatment had the greatest effect on
the expressed genes (top three quartiles of gene ex-
pression). It increased expression of 13.3 and 13.4 %
of unmethylated (quadrant 1) and methylated genes
(quadrant 2), respectively. Functional annotation ana-
lysis revealed enrichment for mitochondrial genes and
apoptosis (Additional file 1: Table S1). Carboplatin
treatment also decreased expression of 6.4 and 7.2 %
of unmethylated and methylated genes in quadrants 1 and
2, respectively (Table 2). Downregulated genes were sig-
nificantly enriched for association with cell division, cell
cycle, and DNA replication (Additional file 1: Table S2).
Combined treatment with decitabine and carboplatin
showed significantly enhanced expression of methylated
silenced genes (quadrant 4). Decitabine alone (at this very
low dose) upregulated expression of 1.2 % genes, carbo-
platin upregulated 1.6 % genes, while decitabine plus
carboplatin combined upregulated 2.5 % (44 of 1778)
methylated silenced genes (Table 2). Functional annota-
tion analysis of the genes upregulated by the combination
showed enrichment for positive regulation of apop-
tosis, cell adhesion, and integrin signaling (Additional
file 1: Table S3).
Thus, at this very low dose, decitabine had a modest
effect on the expression of unmethylated genes while
activating a subset of repressed genes. Carboplatin (used
at the IC50 dose) both activated and repressed unmethy-
lated genes, and showed significant synergy with decita-
bine for those genes showing a high degree of promoter
methylation (i.e., epigenetic synergy).
Epigenetic synergy is independent of DNA demethylation
To search for mechanisms of enhanced gene transcrip-
tion by the combination, we first examined DNA methy-
lation. Carboplatin at 25 μM alone had no effects on
methylation of the long interspersed nuclear element 1
(LINE-1) repetitive elements across the genome or on
the CMV promoter methylation. After treatment with
decitabine at 25 nM, LINE-1 methylation decreased
from 48 to 22 %. When carboplatin at 25 μM was added
to decitabine, it decreased only to 35 % compared with
decitabine alone (Fig. 5a). Similarly, CMV methylation
was 82 % in untreated YB5 cells as measured by bisulfite
pyrosequencing. Decitabine treatment decreased methy-
lation to 28 %, but the addition of carboplatin to
Fig. 3 Baseline gene expression and DNA methylation in YB5 cells. a. Percent DNA methylation at CpG sites within ±500 bp from TSS of 9083
genes (x-axis) vs gene expression at baseline (y-axis). b. Baseline methylation vs expression for the subset of regulated genes showing expression
changes ≥1.5-fold after treatment with decitabine, carboplatin, or their combination. The broken line divides the data into four quadrants: (Q1)
upper left, unmethylated expressed genes; (Q2) upper right, methylated expressed genes; (Q3) lower left, unmethylated silenced genes; and (Q4)
lower right, methylated silenced genes
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decitabine dampened the decrease to 42 % (Fig. 5a). A
possible explanation for the reduced hypomethylating ef-
fect is that carboplatin induced cell cycle arrest, resulting
in less incorporation of decitabine into DNA and less in-
hibition of DNA methyltransferase activity. Indeed, flow
cytometry analysis showed that carboplatin induced cell
cycle arrest in the G2/M phase in a dose-dependent
manner (Fig. 5b). The G2/M proportion in control and
decitabine-treated cells was 10 and 12 %, respectively,
but the addition of carboplatin at 25 μM increased it to
38 and 46 %, respectively. By contrast, the percentages
of G0/G1 cells in control and decitabine-treated cells
were 67 and 68 %, respectively, but the addition of car-
boplatin decreased this to 40 and 28 %, respectively (P <
0.0001, chi-square test).
These data show that synergy in gene activation cannot
be explained by enhanced hypomethylation of promoter
DNA. Generally, decitabine induces hypomethylation at
low doses and cytotoxic effects or a DNA damage re-
sponse that limits hypomethylation at higher doses [12]. It
Table 2 Effect of drug treatment on gene expression in YB5 cells
Methylation Expression Quadrant Analyzed genes Regulated genes Change DAC Carbo DAC + Carbo P value*
<10 % ≥7.08 Q1 5697 1514 Up 177 755 527 <0.0001
Down 58 365 312 <0.0001
≥10 % ≥7.08 Q2 1119 334 Up 64 150 149 <0.0001
Down 14 81 61 <0.0001
<10 % <7.08 Q3 479 22 Up 4 15 7 0.0224
Down 0 0 0 n/a
≥10 % <7.08 Q4 1788 73 Up 21 29 44 0.0119
Down 1 0 0 n/a
*Chi-square test
Fig. 4 Gene expression changes in YB5 cells after drug treatment. Beanplots show changes of expression in 1943 regulated genes compared to
baseline after treatment of YB5 cells with decitabine 25 nM (DAC), carboplatin 20 μM (Carbo), and their combination (DAC + Carbo) in the four
quadrants defined in Fig. 3. The width of the shape sacks represents histograms of data density. The short lines inside the shapes depict individual
data points. Thick horizontal bars show medians. The dotted line behind the shapes shows median of data in all three columns. The expression
changes are plotted in log2 units. a–c Carboplatin treatment results in the largest gene expression changes. d Reactivation of methylated silenced
genes by combined treatment with decitabine and carboplatin
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remains unclear how the hypomethylation response at
different doses correlates with gene activation, and the
carboplatin synergy data suggests a potential disconnect
between the two. To test this further, we examined
DNA methylation and reactivated gene expression at
different doses. As previously reported [22], decitabine-
induced hypomethylation followed a U-shaped pattern
in YB5 and HL60 (Fig. 5c), with inhibited hypomethyla-
tion induction at higher drug concentrations. The doses
of decitabine that induced maximum hypomethylation
were the same for all the genes tested in the respective
cell line (Fig. 5c). For example, decitabine at 100 nM
induced maximum hypomethylation for PDLIM4 and
MLH1 in YB5 while 300 nM induced maximum hypo-
methylation of PDLIM4, PGR, NPM2, and OLIG2 in
HL60. However, the gene expression response to deci-
tabine was quite variable. Some genes (PDLIM4 and
PGR) followed a strict inverse correlation between
Fig. 5 Correlation between gene expression and hypomethylation. a. Carboplatin did not induce hypomethylation of DNA. YB5 cells were treated
with decitabine 25 nM, carboplatin 25 μM, and decitabine + carboplatin for 4 days, respectively. DNA methylation at LINE-1, CMV, and MLH1 promoter CpG
islands was analyzed by bisulfite pyrosequencing. Statistical significance of Bonferroni-corrected t tests is shown by asterisks (***P< 0.001, ****P< 0.0001).
b. Carboplatin induced cell cycle arrest in the G2/M phase. YB5 cells were treated as described above and cell cycle distribution in G0/G1, S, and G2/M was
measured by flow cytometry after propidium iodide staining and analyzed with the Chi-square test (P< 0.0001). c. Decitabine induced hypomethylation
and gene expression in a dose-dependent manner. YB5 and HL60 cells were treated with a variety of logarithmically equally spaced concentrations of
decitabine ranging from 0.03 to 30 μM. DNA methylation (left x-axis, solid lines) and mRNA expression (right x-axis, dotted lines) of MLH1, PDLIM4, PGR, OLIG2,
and NPM2 genes were measured by bisulfite pyrosequencing and qPCR, respectively
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methylation and expression, but for others (MLH1
and OLIG2), we observed a different pattern whereby
high drug concentrations induced a high degree of activa-
tion, despite dampening of the hypomethylation response
(Fig. 5c), just as observed when carboplatin was added to
decitabine.
Decitabine and carboplatin synergy in chromatin
remodeling
As shown by the gene expression studies above and
earlier studies in this model [18, 19], gene transcription
cannot be explained solely by DNA hypomethylation,
but is more closely related to chromatin remodeling. We
therefore examined whether platinum compounds affect
histone modifications and methyl-binding occupancy. By
Western blots, we found no consistent effects of carbo-
platin or the combination on global levels of modified
histones or expression of methyl-CpG-binding domain
protein 2 (MBD2) or methyl-CpG-binding protein 2
(MECP2) (data not shown). We then used chromatin
immunoprecipitation (ChIP) and qPCR at five silenced
gene loci (CMV, p16, ESR1, RARß-2, and MLH1) to study
this further. For the active chromatin mark H3K4me3
(Fig. 6a), decitabine alone increased enrichment an aver-
age of 3.1-fold (range 1.7–4.4), carboplatin increased
enrichment an average of 2.3-fold (range 1.7–2.9), while
the combination increased enrichment an average of 4.4-
fold (range 2.6–5.5-fold, P < 0.0001 for the drug effect
analyzed by two-way repeated measure ANOVA).
Similar results were seen for H3K9Ac, another mark
of gene activation. Compared to controls, mean en-
richment was 1.7-fold with decitabine, 1.9-fold with
carboplatin, and 3.2-fold with the combination (P < 0.0001
for the drug effect, Fig. 6b). For silencing histone marks,
we found no substantial enrichment for H3K27me3 at
these loci, consistent with published data on an inverse
correlation between DNA methylation and H3K27me3 in
cancer cells [23], and H3K9me2 gave inconsistent results,
likely due to the lack of a good antibody (data not shown).
We therefore focused on other components of the silen-
cing complex. DNA methylation recruits methyl-binding
proteins that are associated with histone deacetylases
and a repressive complex, leading to gene silencing.
ChIP for MBD2 binding (Fig. 6c) showed reduced en-
richment (compared to control) of 0.58-fold, 0.43-fold,
and 0.31-fold for decitabine, carboplatin, and the
combination, respectively (P < 0.0001 for the drug ef-
fect, Fig. 6c). For MECP2 (Fig. 6d), we also saw re-
duced enrichment (compared to control) of 0.77-fold,
0.46-fold, and 0.46-fold for decitabine, carboplatin,
and the combination, respectively (P < 0.0001 for the
drug effect).
Fig. 6 Decitabine and carboplatin modulate histones and methyl-binding proteins. We treated YB5 with 25 nM decitabine and/or 25 μM carboplatin
for 4 days. Subsequently, we performed chromatin immunoprecipitation in YB5 controls and treated cells with antibodies against H3K4me3 (a),
H3K9Ac (b), MBD2 (c), and MECP2A (d). We analyzed the abundance of the activation histone marks (H3K4me3, H3K9Ac) and methyl-binding proteins
(MBD2, MECP2) at promoters of CMV, p16, RARB2, ESR1, and MLH1. Statistical significance of Bonferroni-corrected t tests is shown by asterisks
(*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001)
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HP1α targeting by carboplatin
HP1 is a key mediator of gene silencing induced by
promoter DNA methylation. Previous studies indicated
shifts in localization of HP1 in response to DNA damage
[24]. We therefore examined HP1α, HP1β, and HP1γ
expression in nuclear and cytosolic proteins from the YB5
cell line after drug exposure. HP1β and HP1γ were
expressed in both nuclear and cytoplasmic fractions and
were unaffected by decitabine and/or carboplatin treat-
ment. By contrast, HP1α was only present in the nuclear
fraction (Fig. 7a). Treatment with carboplatin alone
reduced HP1α protein expression, and the combination of
carboplatin and decitabine resulted in marked reduction
in HP1α levels in the nucleus (Fig. 7a). This HP1α (CBX5)
gene repression by carboplatin was also detectable at the
level of mRNA expression (Fig. 7b). The data suggested
that HP1α repression could be a key mediator of the ob-
served epigenetic synergy. To test this directly, we per-
formed stable short hairpin inhibitory RNA (shRNA)
knockdown of HP1α in YB5 cells. Compared with the
scrambled shRNA control, knockdown of HP1α partially
phenocopied the effects of carboplatin by increasing ex-
pression of several hypermethylated genes such as GFP,
PDLIM4, and RASSF1A after low-dose decitabine treat-
ment (Fig. 7c). Knockdown of HP1α had little effect on
genes with unmethylated promoters (Fig. 7d).
Discussion
Better therapeutic strategies or targets for drug develop-
ment are needed to improve the efficiency of epigenetic
therapy, expand it to less responsive cancers, and over-
come resistance. Here, we used a live cell-based assay to
evaluate the epigenetic effects of the hypomethylating
drug decitabine in combination with a number of anti-
cancer drugs that are currently active in the clinic.
Most of the chemotherapeutics we tested had limited
effects when used on their own. In order to increase the
effects of low-dose decitabine treatment, we searched for
a synergistic combination that would be worth pursuing
clinically. The combination of decitabine with the DNA
cross-linking agent carboplatin was most effective at
gene reactivation of both GFP and endogenous genes.
Mechanism wise, we show that both decitabine and car-
boplatin reduced binding of MBPs to hypermethylated
genes as well as inhibited HP1α, resulting in an increase
in H3K4me3 and H3K9 acetylation, the active histone
Fig. 7 Carboplatin inhibits HP1α in the YB5 Cells. a. Effects of drug treatment on the expression of HP1 proteins. We isolated cytosolic and nuclear
proteins and performed Western blot analysis of HP1α, HP1β, and HP1γ (* marks a non-specific band). Lamin B1 was used as the internal control for nu-
clear protein expression. β-actin was used as a control for both nuclear and cytosolic proteins. b. Expression of HP1α (CDX5) mRNA after drug treat-
ment measured by real-time PCR and normalized to GAPDH. Statistical significance of gene expression changes was analyzed by one-way ANOVA (P
= 0.005), and Tukey’s multiple comparison tests were used to analyzed the effects of the drug treatments compared to control (**P < 0.01). c. siRNA
knockdown of HP1α increased expression of genes hypermethylated in the YB5 cells. The expression levels from four experiments were normalized to
GAPDH and compared using t test (*P < 0.05). d. Knockdown of HP1α had little effect on genes with unmethylated promoters (P > 0.05)
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marks associated with gene reactivation. The fact that
decitabine and platinum analogs exerted their effects
through different mechanisms makes this combination
intriguing and suggests potential applicability in the
clinic. In terms of epigenetic therapy, the most effective
drug combination previously reported is DNA methyl-
transferases inhibitors and HDAC inhibitors [27]. How-
ever, the clinical results on this combination have been
disappointing in randomized clinical trials to date [28,
8], perhaps because of limited single-agent activity of
HDAC inhibitors. Combination therapy using a hypo-
methylating agent with cytotoxic platinum analogs might
be a more effective way to achieve a better response,
particularly in solid tumors. Synergy of decitabine with
platinum analogs has previously been reported in mul-
tiple tumor models [29–31], and the combination of
decitabine with carboplatin showed promising effects in
several clinical trials in platinum-resistant ovarian cancer
[32–35]. This was explained by reactivation of genes
silenced by DNA methylation such as the mismatch re-
pair gene MLH1 [29, 20, 12]. In this study, we suggest
that disruption of HP1α binding is an additional mech-
anism to explain the synergy seen in the combination of
decitabine with carboplatin.
It is important to note that we investigated low doses
of decitabine in the synergy experiments described
here. In contrast to the maximum tolerated dose ap-
proach used for conventional cytotoxic therapy in can-
cer, epigenetic therapy is most effective using low-dose
regimens for DNA demethylating agents [25, 26]. In-
deed, decitabine used at the low concentration of
25 nM induced significant hypomethylation and gene
reactivation in YB5 cells with negligible toxicity and no
effect on the cell cycle. This dose is even lower than
the peak concentration of decitabine achieved with
current treatment regimens, and the data are consistent
with our observation in clinical trials that treatment of
cancer cells with clinically relevant low doses of decita-
bine and azacitidine can exert sustained antitumor ef-
fects and are less toxic [25, 8]. Nevertheless, we also
found that the gene expression response to decitabine
at different concentrations was quite variable for differ-
ent genes, even though the demethylation pattern was
very similar. At higher doses, decitabine significantly
increased gene expression of some hypermethylated
genes without additional effects on DNA methylation.
It is possible that decitabine-induced cytotoxicity and
DNA damage at high doses might recruit a complex of
transcription factors or other pathways, resulting in in-
creased gene reactivation independent of DNA demeth-
ylation. These data illustrate the complexity of the
dose-response with hypomethylating drugs and point to
the potential use of different doses depending on the
desired molecular outcome.
We screened the combination of decitabine with
several categories of DNA-damaging agents; however,
only platinum analogs showed epigenetic synergy. We
examined several possible mechanisms for carboplatin-
induced gene reactivation. Carboplatin forms interstrand
and intrastrand cross-linking with guanine (G), which is
likely to influence DNA-binding protein complexes either
through blocking DNA-binding sites or changing DNA
configuration. However, it is unlikely that this acts on
every gene reactivated in enough cells to have a meas-
urable effect on gene expression, leading us to consider
indirect mechanisms. We found no direct effects of car-
boplatin on DNA methylation or bulk histone modifica-
tions, but we did document substantial nuclear HP1α
depletion, particularly in the decitabine/carboplatin
combination. Interestingly, siRNA to HP1α partially
phenocopied the effects of carboplatin.
HP1 is a major element in the DNA damage re-
sponse recruited to the sites of DNA damage [36–38].
Double-strand breaks in DNA promote transient for-
mation of repressive chromatin through loading HP1
[39]. However, our data suggest that, at least for plat-
inum drugs, the opposite effect on HP1α can also be seen.
Intriguingly, loosening of HP1 from DNA shortly after in-
duction of DNA damage has been reported [40]. It is pos-
sible that with longer time, HP1α is actually degraded,
resulting in the depletion we observed. HP1α is part of a
central pathway for epigenetic silencing whereby DNA
methylation recruits MBPs which in turn recruit HDACs
and HMTs. This results in histone H3K9 methylation
which triggers HP1 binding, chromatin condensation, and
a silenced state that, itself, may trigger more DNA methy-
lation [41-43]. The HP1 variants in mammalian cells in-
clude HP1α, HP1β, and HP1γ. However, we observed that
carboplatin mainly inhibited HP1α, which was the only
purely nuclear HP1 family member. All HP1 proteins
share the same architecture that consists of a chromodo-
main and a chromoshadow domain, connected by a hinge.
HP1α shows unique DNA-binding properties in that it
binds preformed nuclear chromatin through strong HP1-
hinge–DNA interactions rather than through its chromo-
domain [44]. The DNA-binding activity of the hinge
contributes to the high affinity and selective binding of
HP1α to tetranucleosomes containing H3K9me3 [45].
This unique binding pattern may explain the selective
degradation of HP1α by DNA cross-linking. It is also
worth noting that the non-cross-linking O6-guanine
methylating agent temozolomide [46] also showed
synergistic reactivation of GFP expression in YB5 cells
at high doses (Table 1). Carboplatin has been shown
to deplete methylguanine methyltransferase [47], and
it is therefore possible that an increase in genome-
wide O6-guanine methylation may be involved in the
observed gene reactivation.
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Conclusions
In summary, using this live cell screening system, we
uncovered unexpected epigenetic synergy between deci-
tabine and platinum analogs which is worth pursuing
clinically. While decitabine is currently being used as a
“priming” therapy to sensitize to platinum, our data
suggest that the two drugs could potentially be admin-
istered concurrently to maximize dual cytotoxic and
epigenetic effects.
Availability of supporting data
The data discussed in this publication have been de-
posited in NCBI’s Gene Expression Omnibus [58] and
are accessible through GEO Series accession number
GSE66296.
Methods
Cell culture and treatment protocols
The human colon cancer cell line SW48 and leukemia
cell lines HL60 and K562 were obtained from American
Type of Culture Collection. SW48 was grown in L-15
medium plus 10 % fetal calf serum (FCS) in plastic tissue
culture plates in a humidified atmosphere containing
1 % CO2 at 37 °C. Leukemia cell lines were grown in
RPMI 1640 medium supplemented with 10 % FCS in a
humidified atmosphere containing 5 % CO2 at 37 °C.
For the growth inhibition assay, cells were split at a
density of 1 × 105/mL in 5 mL of medium 24 h before
treatment. Different concentrations of drugs were added
to the medium either separately or in combination.
The doses that inhibited 50 % proliferation (IC50)
were analyzed by the median-effect method. We used
fixed ratios of 1/8, 2/8, 3/8, 4/8, 6/8, and 8/8 IC50
for decitabine and carboplatin for each respective cell
line. In vitro cytotoxicity was assayed in triplicate by
the following experimental conditions: control, decita-
bine, tested drug (listed in Table 1), and decitabine +
tested drug. The proportion of live cells in treated
plates was measured by counting cells in
hemocytometer based on trypan blue exclusion. The
effects of combinations were estimated using the Cal-
cuSyn software (Biosoft) based on the median-effect
method by Chou and Talalay [48].
FACS analysis
GFP expressing cell percentages were measured using
a Becton Dickinson FACSCalibur Flow Cytometer at
the University of Texas MD Anderson Cancer Center
Flow Cytometry Core Facility. For GFP reactivation
after a 96-h incubation with daily decitabine, the cells
were trypsinized and resuspended in growth medium. Cell
cycle analysis was performed by DNA quantitation after
propidium iodide staining. Flow cytometry data were proc-
essed using FlowJo software (Tree Star, Inc, Ashland, OR).
Bisulfite pyrosequencing for methylation analysis
Bisulfite treatment was performed as reported previ-
ously [49, 50]. Genomic DNA was denatured by 0.2 M
NaOH at 37 °C for 10 min followed by incubation with
freshly prepared 30 μL of 10 mM hydroquinone and
520 μL of 3 M sodium bisulfite (pH 5.0) at 50 °C for
16 h. DNA was purified with a Wizard Miniprep
Column (Promega, Madison, WI), desulfonated with
0.3 M NaOH at 25 °C for 5 min, precipitated with
2.5 M ammonium acetate and ethanol, and dissolved in
50 μL of TE buffer (Tris-HCl 10 mM, EDTA 1 mM, pH
8.0). Bisulfite-treated DNA (40–80 ng) was amplified
with gene-specific primers by polymerase chain reac-
tion (PCR). Primer sequences for the five genes and
LINE-1 elements analyzed are shown in Additional file
2: Table S4. We measured levels of DNA methylation
as the percentage of bisulfite-resistant cytosines at CpG
sites by pyrosequencing with the PSQ HS 96 Pyrose-
quencing System (Biotage, Charlottesville, VA) and
Pyro Gold CDT Reagents (Biotage) as previously de-
scribed [51].
RNA extraction and cDNA synthesis
Total cellular RNA was extracted by TRIzol reagent
(Life Technologies). RNA was eluted with RNase-free
water, quantified by spectrophotometry and used for
first-strand complementary DNA (cDNA) synthesis ac-
cording to the manufacturer’s protocol (Applied Biosys-
tems). Three micrograms of RNA was reversely
transcribed to single-stranded cDNA. The reverse tran-
scription was performed in a total volume of 50 μL con-
taining 0.2 mM of each dNTP (Amersham Pharmacia
Biotech, Piscataway, NJ), 10 μM of random hexanucleo-
tide primers (Invitrogen), 200 U Moloney murine
leukemia virus reverse transcriptase (M-MLV RT) (Pro-
mega, Madison, WI), and 25 U RNAsin (Promega) at
37 °C for 2 h. The obtained cDNA was stored at −80 °C.
Quantitative reverse transcription-PCR
Real-time quantitative reverse transcription-PCR (qRT-
PCR) was done with the ABI 7000 Sequence Detector
(Applied Biosystems). We used ready-made TaqMan®
assays on the analyzed genes and custom-designed
GAPDH primers and TaqMan® probe [52] (Applied
Biosystems). Reactions for qRT-PCR were done with
the TaqMan® universal PCR Master Mix kit (Applied
Biosystems) in 96-well plates. Each sample was mea-
sured in triplicate. PCR was run using the following
conditions: an initial denaturation step of 95 °C for
10 min followed by 40 cycles at 95 °C for 15 s and 60 °
C for 1 min. The resulting data were analyzed with ABI
Prism 7000 SDS software (Applied Biosystems). The
threshold cycles (CT) were determined, and the
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differences in the CT values for GAPDH and selected
genes were calculated.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) analyses were
performed as described previously [31]. Briefly, cells
were fixed in 1 % formaldehyde and lysed followed by
sonication shearing using the Bioruptor sonicator
(Diagenode, Belgium). After centrifugation, the soluble
chromatin was subjected to immunoprecipitation with
antibodies against different modified histones. Anti-
bodies used were directed against histone H3 (ab1791,
Abcam, Cambridge, MA), histone H3K9 acetylation (07-
030, Millipore, Billerica, MA), trimethyl-histone H3 (Lys4)
antibody (04-745, Millipore), MeCP2 (ABE171, Millipore),
MBD2 (ab38646, Abcam), histone H3K27 trimethyla-
tion (07-449, Millipore), and IgG (sc-2027, Santa Cruz
Biotechnology, Santa Cruz, CA) as a negative control.
The complexes were drawn off with protein A-agarose
and G-agarose beads (ratio 3:1) and washed sequentially
with low-salt, high-salt, LiCl, and Tris-EDTA buffers and
were finally extracted with freshly prepared 1 % SDS-
0.1 M NaHCO3. Samples were brought to 65 °C for 4 h to
reverse DNA and protein cross-links, and DNA was then
purified with a Qiagen DNA extraction kit. 1.0 × 106 cells
were used per antibody pulldown. Quantitative analyses
were done by qPCR using 6-FAM-labeled probes tar-
geting three regions of the CMV-EGFP locus (Applied
Biosystems). Sequences of all primers and probes are
in Additional file 2: Table S5.
Cell lysate and histone preparation and Western blots
Total histones were prepared by acidic extraction and re-
solved on 15 % SDS-polyacrylamide gels as described [44].
Cell lysates of nuclear and cytosolic proteins were pre-
pared using NE-PER™ kit (78833, Pierce). Antibodies used
for Western blotting were directed against pan-acetylated
histone H4 (06-866, Millipore), histone H4 (07-108,
Millipore), histone H3 (ab1791, Abcam), trimethyl-his-
tone H3 (Lys4) antibody (04-745, Millipore), histone H3K9
acetylation (07-030, Millipore), histone H3K27 trimethyla-
tion (07-449, Millipore), HP1α (ab77256, Abcam), HP1β
(ab10478, Abcam), HP1γ (ab10480, Abcam), MeCP2
(ABE171, Millipore), MBD2 (ab38646, Abcam), and lamin
B1 (ab16048, Abcam).
Gene expression microarrays
Gene expression microarray analyses were conducted
using the Agilent Whole Genome 4x44K v2 Micro-
array (G4112F). Hybridized arrays were scanned
using the Agilent G2505B Scanner and processed in
R using Bioconductor packages geneplotter, limma,
and agilp [53, 54].
Digital restriction enzyme analysis of methylation
Genome-wide analysis of DNA methylation by digital re-
striction enzyme analysis of methylation (DREAM) was
done as previously described [21]. Briefly, 5 μg of SW48
genomic DNA spiked in with 10 pg of methylation stan-
dards were digested with 100 units of SmaI endonucle-
ase (NEB) for 3 h at 25 °C. Subsequently, 100 units of
XmaI endonuclease (NEB) were added and the digestion
was continued for an additional 16 h at 37 °C. Digested
DNA was purified and incubated for 30 min at 37 °C
with 15 units of Klenow Fragment 3′→ 5′ exo-DNA
polymerase (NEB) to fill in the recesses and add dA
overhangs at 3′ ends of the DNA fragments. Illumina
paired-end sequencing adapters were then ligated using
Rapid T4 DNA ligase (Enzymatics). The ligation mix
was size selected by electrophoresis in 2 % agarose, and
fragments with apparent sizes of 250–350 and 350–
500 bp were separately amplified with Illumina paired-
end PCR primers, iProof high-fidelity DNA polymerase
(Bio-Rad Laboratories) master mix, and 18 cycles of
amplification. The resulting libraries were purified with
AMPure magnetic beads (Agencourt). The libraries were
sequenced by paired-end 36 nt sequencing on Illumina
HiSeq 2000 at the MD Anderson Center for Cancer
Epigenetics. After mapping the sequencing reads to
the reference human genome (hg18), we determined
methylation levels at target CpG sites as described
previously [21]. The results were assembled for further
analysis in the Microsoft Access relational database con-
taining the full annotation of all SmaI/XmaI sites in the
human genome.
HP1α knockdown
siRNA oligo GGAUUGCCCUGAGCUAAUUUU (Ambion)
was transfected to YB5 cells using Lipofectamine
RNAiMAX reagent (Life Technologies) following the
manufacturer’s protocol. Mock transfection with Li-
pofectamine only was used as the control.
Statistics
GraphPad Prism 5 software was used for statistical
analyses. Two-way ANOVA was used to test for ef-
fects of drug treatment, and t tests with Bonferroni
correction for multiple comparisons were used to as-
sess the effects on individual genes. One-way ANOVA
with Tukey’s multiple comparison post-tests was used
for the analysis of gene expression changes. The Spearman
method was used to assess correlation between DNA
methylation and gene expression. Two-tailed P < 0.05
was considered a significant difference. Chi-square
test was used for the numbers of regulated genes.
Functional gene annotation, enrichment analysis was
performed using GeneCodis online tool (http://gene-
codis.cnb.csic.es) [55–57].
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Additional files
Additional file 1: Table S1. Top functional annotation categories of
genes upregulated by carboplatin. Table S2. Top functional annotation
categories of genes downregulated by carboplatin. Table S3. Functional
annotation of genes upregulated by decitabine and carboplatin (DAC
+Carbo).
Additional file 2: Table S4. Primers for bisulfite pyrosequencing.Table
S5. Primers for ChIP Q-PCR.
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